Evaluation of c-myc and CCNE2 amplification in breast cancer with quantitative multi-gene fluorescence in-situ hybridization

Chinese Journal of Pathology

Volumn 43, Issue 7, 2014, Pages 455-458

  Zhishuang, Li ^a   Qingyong, Meng ^a   Qiong, Yu ^a   Zhiqiang, Zhou ^a   Li, Li ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Breast neoplasms; Cyclin E; Genes, myc; In situ hybridization, fluorescence

Indexed keywords

CCNE2 PROTEIN, HUMAN; CYCLINE;

ANEUPLOIDY; BREAST TUMOR; CARCINOMA IN SITU; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; INTRADUCTAL CARCINOMA; ONCOGENE MYC; PAGET NIPPLE DISEASE; PROCEDURES; TISSUE MICROARRAY;

ANEUPLOIDY; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLINS; FEMALE; GENE AMPLIFICATION; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; TISSUE ARRAY ANALYSIS;

EID: 84905639833     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2014.07.006     Document Type: Article

References (14)

1. Geng Y, Yu Q, Whoriskey W, et al. Expression of cyclins El and E2 during mouse development and in neoplasia [J]. Proc Natl Acad Sci USA, 2001, 98(23):13138-13143.
2. Miiller-Tidow C, Metzger R, KUgler K, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer[J]. Cancer Res, 2001, 61(2):647-653.
3. Lakhani SR, Ellis LO, Schnitt SJ, et al. WHO classification of tumours of the breast[M]. 4th ed. Lyon: IARC Press, 2012.
4. Elston CW, Ellis IO. Assessment of histological grade [M]//Elston CW, Ellis IO. The breast New York: Churchill Livingstone, 1998:356-384.
5. Steinbeck RG. The DNA content of chromosome division figures and interphase nuclei classifies ulcerative colitis[J]. Eur J Cancer, 1998, 34(1):175-181.
6. Li L, Mu K, Zhou G, et al. Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer[J]. Br J Cancer, 2008, 99(3):513-519.
7. Liao DJ, Dickson RB. c-Myc in breast cancer[J]. Endocr Relat Cancer, 2000, 7(3):143-164.
8. Park K, Kwak K, Kim J, et al. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers[J]. Hum Pathol, 2005, 36(6):634-639.
9. Barnes DM, Gillett CE. Cyclin Dl in breast cancer[J]. Breast Cancer Res Treat, 1998, 52(1-3):1-15.
10. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situhybridization[J]. Mod Pathol, 1997, 10(7):720-727.
11. Payton M, Scully S, Chung G, et al. Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors [J]. Oncogene, 2002, 21(55):8529-8534.
12. Walker LC, McDonald M, Wells JE, et al. Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma[J]. PLoS One, 2013, 8(7):e70790.
13. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer[J]. Lancet, 2005, 365(9460):671-679.
14. Van Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer [J]. Nature, 2002, 415(6871):530-536.